Loading...
XSHE002873
Market cap311mUSD
Dec 27, Last price  
9.84CNY
1D
1.86%
1Q
7.54%
IPO
12.44%
Name

Guiyang Xintian Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002873 chart
P/E
28.14
P/S
2.39
EPS
0.35
Div Yield, %
1.87%
Shrs. gr., 5y
1.28%
Rev. gr., 5y
6.56%
Revenues
954m
-12.29%
330,088,865406,126,853454,125,518521,910,598633,186,158681,714,129694,259,400773,337,464750,946,390969,844,4721,087,673,294953,981,876
Net income
81m
-27.48%
26,392,57015,094,99233,123,98142,010,47157,069,48466,116,84470,975,49671,422,16572,546,44599,475,885111,518,64480,871,062
CFO
78m
+2.59%
21,407,33113,879,02237,304,16140,731,17161,343,77862,060,03547,592,57933,728,459175,767,527124,300,30475,818,17477,782,320
Dividend
Jun 25, 20240.07 CNY/sh
Earnings
Apr 10, 2025

Profile

Guiyang Xintian Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of Chinese medicines for various diseases in China. The company offers formulation products, which include hard capsules, gels, mixtures, granules, and tablets. Its products are used for the treatment of antitumor, gynecological, urinary, breast thyroid, blood, heat, oral, anti-cold, and cardiovascular diseases. The company was founded in 1995 and is based in Guiyang, China.
URL
http://www.gyxtyy.com/
IPO date
May 19, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
953,982
-12.29%
1,087,673
12.15%
969,844
29.15%
Cost of revenue
686,291
846,417
747,205
Unusual Expense (Income)
NOPBT
267,691
241,257
222,639
NOPBT Margin
28.06%
22.18%
22.96%
Operating Taxes
11,546
5,493
16,043
Tax Rate
4.31%
2.28%
7.21%
NOPAT
256,145
235,764
206,596
Net income
80,871
-27.48%
111,519
12.11%
99,476
37.12%
Dividends
(42,527)
(19,887)
(14,015)
Dividend yield
1.40%
0.56%
0.40%
Proceeds from repurchase of equity
(2,989)
(1)
12,790
BB yield
0.10%
0.00%
-0.36%
Debt
Debt current
366,929
323,771
268,343
Long-term debt
214,250
168,122
168,095
Deferred revenue
20,834
22,147
24,513
Other long-term liabilities
21,423
3,357
3,417
Net debt
59,668
(70,347)
51,457
Cash flow
Cash from operating activities
77,782
75,818
124,300
CAPEX
Cash from investing activities
(96,697)
Cash from financing activities
56,483
31,544
FCF
163,340
29,187
117,922
Balance
Cash
138,331
100,779
152,478
Long term investments
383,180
461,462
232,502
Excess cash
473,812
507,857
336,488
Stockholders' equity
943,902
955,592
679,539
Invested Capital
1,232,767
1,127,088
994,790
ROIC
21.71%
22.22%
21.44%
ROCE
15.53%
14.51%
16.68%
EV
Common stock shares outstanding
244,545
243,809
244,697
Price
12.46
-13.95%
14.48
0.36%
14.43
73.92%
Market cap
3,047,032
-13.69%
3,530,356
-0.01%
3,530,624
76.40%
EV
3,201,465
3,460,008
3,582,081
EBITDA
292,414
266,706
245,445
EV/EBITDA
10.95
12.97
14.59
Interest
12,930
10,675
16,604
Interest/NOPBT
4.83%
4.42%
7.46%